XML 43 R27.htm IDEA: XBRL DOCUMENT

Other Non-Current Liabilities	12 Months Ended
Other Non-Current Liabilities	Dec. 31, 2023
Payables and Accruals [Abstract]
Other Non-Current Liabilities	Other Non-Current Liabilities Included within other non-current liabilities at December 31, 2023 and 2022 is $1,356 and $1,209, respectively, relating to assumed contingent liabilities. As part of the acquisition of Discuva Limited in December 2017, the Company assumed certain contingent liabilities as certain employees, former employees and former directors of Discuva Limited are eligible for payments from Discuva Limited based on specified development and clinical milestones related to proprietary product candidates developed under the Discuva Platform. The timing of these potential payments is uncertain. In conjunction with the significant change in the Company’s strategy and shift in focus to the therapeutic area of oncology, the Company determined that it will cease further investment in the Discuva platform and evaluate further options for the use of the Discuva Platform. As a result, management has revised the estimated presented value of these payments and remeasured the contingent liabilities. This resulted in recording a gain on remeasurement of liabilities of $1,265 during the year ended December 31, 2022, which is included net as part of the research and development expenses in the consolidated statement of operations and comprehensive loss. There were no remeasurement losses or gains recognized during the year ended December 31, 2023.